The Motley Fool Previous Page


More Patients! But, Will They Pay?

http://www.fool.com/investing/general/2012/10/09/more-patients-but-will-they-pay.aspx

Brian Orelli
October 9, 2012

VIVUS (Nasdaq: VVUS  ) ¬†shot up 10% on Monday after announcing that Express Scripts (Nasdaq: ESRX  ) would sell its obesity drug Qsymia. When your drug is only available via mail-order pharmacies, getting the nation's largest pharmacy benefit manager on board to sell it is a prudent move. A double-digit move appears reasonable on the surface.

I figured the deal was already factore